B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tema GLP-1, Obesity & Cardiometabolic ETF (NQ: HRTS )

33.65 +0.45 (+1.36%)
Streaming Delayed Price Updated: 11:55 AM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,062
Open 33.23
Bid (Size) 33.60 (4)
Ask (Size) 33.68 (6)
Prev. Close 33.20
Today's Range 33.23 - 33.65
52wk Range 26.26 - 36.03
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on company's bottom line. 
Via Benzinga
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. 
Via Benzinga

Performance

YTD
+9.77%
+9.77%
1 Month
-1.84%
-1.84%
3 Month
-3.88%
-3.88%
6 Month
+2.72%
+2.72%
1 Year
+26.38%
+26.38%

More News

Read More
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
Via Benzinga
Topics ETFs
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
Via Investor's Business Daily
Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply
Via Benzinga
Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test
Via Investor's Business Daily
Healthcare ETFs For The Weight-Loss Drug Boom And Beyond
Via Talk Markets
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Via Investor's Business Daily
Ozempic, Weygovy – Obesity And Heart Health Constitute A Major Market That Is Only Growing
Via Benzinga
Topics ETFs
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Via Benzinga
EXCLUSIVE: Tema ETFs' Innovative Thematic Investing Approach Targets New Opportunities Beyond The Fads
Via Benzinga
Topics ETFs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.